在儿科创伤中使用特兰胺酸剂量:基于成人创伤患者群体药动力学建模的剂量模拟
Gideon Stitt1, Kevin Downes2,3,4, Athena Zuppa4
1Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
Transfusion
|December 23, 2025
概括
在儿童创伤患者中,25 mg/kg的静脉注射玻尿酸 (TXA) 接近成人Cmax. 然而,对于与创伤相关的出血儿童的类似药物总暴露,可能需要更频繁的剂量.
科学领域:
- 儿科创伤护理 儿童创伤护理
- 药理动力学 药理动力学
- 管理出血 管理出血
背景情况:
- 创伤是1岁以上儿童死亡的主要原因.
- 流血是儿童创伤后最常见的可预防的死亡原因.
- 对于儿童的抗纤维素催化剂 (如酸 (TXA)) 的最佳剂量尚不清楚.
研究的目的:
- 为了确定儿童创伤患者的TXA剂量,模仿成人暴露.
- 使用来自成年创伤患者的群体药理动力学 (popPK) 模型.
主要方法:
- 基于模型的模拟将成人TXA popPK模型推断到儿科患者.
- 使用共变量值模拟了一个虚拟的儿科创伤人群.
- 应用全米缩放来预测儿童的TXA PK概况.
主要成果:
- 在儿童创伤患者中,TXA的25 mg/kg静脉注射量接近成人2g静脉注射量的Cmax.
- 没有测试剂量 (20-35 mg/kg) 达到成人AUC0-4h或AUC0-8h.
结论:
- 预计25 mg/kg的IV TXA玻尿酸在儿童和成年人中达到类似的药物度峰值 (Cmax).
- 儿童创伤患者可能需要更频繁的TXA剂量,以获得可比的药物总暴露.
相关概念视频
Drug Dosing: Infants and Children
229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Drug Distribution
234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133


